Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone

Akira Oshima, MD; Teruhiko Imamura, MD, PhD; Nikhil Narang, MD; Koichiro Kinugawa, MD, PhD

Background: The effects of mineralocorticoid receptor antagonists, including the newly introduced esaxerenone, on renal function remain uncertain.

Methods and Results: This retrospective study was performed on patients who received esaxerenone for resistant hypertension between November 2019 and June 2020. Trends in the estimated glomerular filtration rate (eGFR) were compared between the 6-month period before esaxerenone treatment (pre-treatment period) and the 6-month treatment period on esaxerenone. Twenty-six patients (15 men), with a median age of 70 years (interquartile range [IQR] 51–73 years) and a median systolic blood pressure of 146 mmHg (IQR 139–156 mmHg), were included in the study and completed 6 months of esaxerenone therapy without any adverse events. eGFR decreased significantly during the pre-treatment period (from 66.6 to 59.5 mL/min/1.73 m²; P=0.003), whereas eGFR was unchanged during the treatment period (from 59.5 to 61.8 mL/min/1.73 m²; P=0.15). The median change in eGFR differed significantly between the treatment and pre-treatment periods (3.8 [IQR –4.2, 6.8] vs. –6.1 [IQR –11.1, 1.8] mL/min/1.73 m², respectively; P=0.008).

Conclusions: Esaxerenone may have renoprotective effects when administered to treat hypertension. Further studies are needed to understand which patient populations may see greater renoprotective benefits with esaxerenone.

Key Words: Blood pressure; Chronic kidney disease; Mineralocorticoid receptor antagonist

Patients with hypertension refractory to various antihypertensive agents, including β-blockers, renin-angiotensin system (RAS) inhibitors, and diuretics, are clinically challenging to manage. Mineralocorticoid receptor antagonists (MRAs) are tried in cases of such refractory hypertension. However, conventional MRAs, including spironolactone and eplerenone, can cause sex hormone-related adverse events and hyperkalemia, necessitating discontinuation. Furthermore, these medications may have a negative effect on preserving renal function. Of note, eplerenone is contraindicated for those with an estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m². The interplay of untreated hypertension and chronic kidney disease can make clinical management very challenging.

Esaxerenone is a newly introduced MRA that specifically inhibits excessive mineralocorticoid receptor activity. A recent Phase III study demonstrated that adding esaxerenone to existing RAS inhibitors in patients with Type 2 diabetes and microalbuminuria improved albuminuria. We hypothesized that mid-term esaxerenone therapy may suppress the gradual progression of renal impairment and, in the present study, investigated the effect of esaxerenone therapy on the preservation of eGFR by comparing a period prior to esaxerenone therapy (pre-treatment period) to a period on esaxerenone among a hypertensive cohort.

Methods

Patient Selection

Consecutive patients who received esaxerenone for the treatment of resistant hypertension between November 2019 and June 2020 were considered for inclusion in this retrospective study. Patients with an eGFR <30 mL/min/1.73 m² or those with serum potassium >5.0 mEq/L were not given esaxerenone. Patients with malignancy or secondary hypertension were excluded from the study. Patients without comprehensive clinical data obtained at 3 time points (in the 6 months before esaxerenone, at baseline, and after 6 months esaxerenone treatment) were also excluded. The study protocol was approved by the University of Toyama Ethics Committee (No. RCOI2019584). All participants...
its dose were at the discretion of the attending physicians, and esaxerenone therapy was performed according to the institutional protocol of the Second Department of Internal Medicine, University of Toyama, as described below.

Esaxerenone was initiated at a dose of 2.5 mg/day, except in patients with an eGFR between 30 and 60 mL/min/1.73 m², in whom esaxerenone was initiated at a dose of 1.25 mg/day. Systemic blood pressure (SBP) and serum potassium concentrations were followed up at least once per month. When the serum potassium concentration exceeded 5.0 mEq/L, down-titration of the dose of esaxerenone was considered. When serum potassium concentrations exceeded 5.5 mEq/L, stopping esaxerenone was considered.

Data Collection
Information on patient demographics, medications, hemodynamics, and laboratory data, including eGFR, serum potassium concentrations, and the urinary albumin-to-creatinine ratio (UACR), at the time of esaxerenone initiation (which was defined as baseline), was retrieved from patient records. Similarly, laboratory data were retrieved 6 months before and after the initiation of esaxerenone. The primary outcome in this study was the trend in eGFR during the observational period (i.e., during the pre-treatment period, at baseline, and then after 6 months treatment).

Statistical Analyses
Continuous variables are presented as median values with the interquartile range (IQR). Categorical variables are presented as numbers and percentages. Trends were assessed using the Friedman test and ad hoc Wilcoxon signed-rank test or the Cochran Q test and ad hoc McNemar test. Logistic regression analyses were used to investigate factors associated with any increases in eGFR during esaxerenone therapy. Variables with P<0.10 in the univariate analysis were included in the multivariate analysis.

Table 1. Baseline Characteristics

| Demographics | n (%) | Median [IQR] |
|--------------|-------|-------------|
| Age (years)  | 70 [51–73] |
| Male sex     | 15 (58) |
| Body surface area (m²) | 1.63 [1.55–1.78] |
| Atrial fibrillation | 6 (23) |
| Heart failure | 6 (23) |
| Ischemic heart disease | 2 (8) |
| Diabetes     | 5 (19) |
| Mediations   |       |
| β-blocker    | 10 (38) |
| ACEI/ARB     | 20 (77) |
| Calcium channel blocker | 15 (58) |
| Diuretics    | 9 (35) |
| Laboratory data |       |
| Serum potassium (mEq/L) | 4.1 [3.8–4.3] |
| UACR (mg/g creatinine) | 26.5 [22.5–31.5] |
| eGFR (mL/min/1.73 m²) | 59.5 [49.7–70.5] |

Data are given as the median [interquartile range] or as n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II antagonist; DBP, diastolic blood pressure; SBP, systolic blood pressure; UACR, urinary albumin-to-creatinine ratio.

Figure 1. Trends in estimated glomerular filtration rate (eGFR) from 6 months before esaxerenone treatment (Pre 6Mo; pre-treatment period) to baseline (initiation of esaxerenone) to 6 months after esaxerenone (Post 6Mo). (A) In individual patients. (B) Box plots showing the median (horizontal lines) and interquartile range (boxes) of eGFR at each time point with the median value indicated by the horizontal line; whiskers show the range. eGFR decreased significantly during the pre-treatment period (green arrow), but was relatively unchanged during the treatment period (blue arrow). MRA, mineralocorticoid receptor antagonist.
Statistical analyses were performed using SPSS Statistics 22 (IBM Corp., Armonk, NY, USA). Two-sided P<0.05 was considered statistically significant.

**Results**

**Baseline Characteristics**
In all, 26 patients (median age 70 years [IQR 51–73 years]; 15 men) were included (Table 1). Six patients had heart failure, 6 had atrial fibrillation, and 5 had diabetes. All patients had hypertension; the median SBP was 146 mmHg (IQR 139–156 mmHg). Eight patients were receiving ≥3 antihypertensive agents. No patients had received MRAs previously. The Median eGFR was 59.5 mL/min/1.73 m² (IQR 49.7–70.5 mL/min/1.73 m²) and the median serum potassium concentration was 4.1 mEq/L (3.8–4.3 mEq/L).

Esaxerenone was administered at a dose of 2.5 mg/day in 16 patients and at 1.25 mg/day in 10 patients. All patients continued esaxerenone therapy for the entire 6-month observational period without any obvious adverse events.

**Trends in eGFR (Primary Outcome)**
Trends in eGFR in individual patients during the entire study period are shown in Figure 1A. During the 6-month period prior to the initiation of esaxerenone, eGFR decreased significantly from 66.6 to 59.5 mL/min/1.73 m² (P=0.003; Figure 1B, with the median change in eGFR being −6.1 mL/min/1.73 m² [IQR −11.1, 1.8 mL/min/1.73 m²; Figure 2]. eGFR did not change during the 6-month period when patients were on esaxerenone: from 59.5 to 61.8 mL/min/1.73 m² (P=0.15; Figure 1B). The median change in eGFR was 3.8 mL/min/1.73 m² (IQR −4.2, 6.8 mL/min/1.73 m²; Figure 2), which was significantly higher than the change during the pre-treatment period (P=0.008).

**Trends in Other Data**
SBP decreased significantly following the initiation of esaxerenone (P=0.034; Table 2); however, the prescription rates of antihypertensive agents remained unchanged (P>0.05 for all). Serum potassium concentrations increased significantly from 4.1 to 4.2 mEq/L (P=0.013) after the initiation of esaxerenone, but no patient had serum potassium >5.0 mEq/L during esaxerenone therapy. UACR did not change during the pre-treatment period (P=0.10), but decreased significantly following the initiation of esaxerenone (P=0.001).

**Factors Associated With Any Increases in eGFR**
Among all baseline variables, a smaller body surface area (P=0.053) and the dose of esaxerenone (P=0.040) were significantly associated with any increases in eGFR. In the multivariate analysis, the association of these two variables with any increase in eGFR did not reach statistical significance (P=0.059 and P=0.051 for body surface area and dose of esaxerenone, respectively).

**Discussion**
In this study we investigated the effect of esaxerenone...
therapy on renal function in patients with hypertension. The major findings of the study were that: (1) esaxerenone decreased blood pressure without any adverse events during the 6-month observation period; (2) the median change in eGFR was significantly higher during the 6-month therapeutic period on esaxerenone than during the pre-treatment period; and (3) UACR decreased significantly following the initiation of esaxerenone.

**Efficacy and Safety of Esaxerenone Therapy**

SBP decreased by 12 mmHg during the 6-month period of esaxerenone therapy in this study. This is relatively lower than the 18-mmHg decrease reported in a study that included patients with chronic kidney disease and the 17-mmHg decrease reported in the Phase III study that included patients with normal kidney function. This discrepancy may stem from a relatively lower baseline SBP (median <150 mmHg) in the present study. A median SBP of 134 mmHg during the post-treatment period would be an acceptable value to prevent an increase in cardiovascular disease risk.

Hyperkalemia is a well-known adverse event and a leading cause of the discontinuation of MRAs. The incidence of hyperkalemia during esaxerenone therapy is quite low. In the Phase III study that included patients with diabetic kidney disease, serum potassium increased only 0.2 mEq/L during the esaxerenone therapy. In that study, esaxerenone was discontinued in only 4% of patients. In the present study, the median increase in serum potassium concentrations was 0.1 mEq/L, and no patient discontinued esaxerenone. Another study including patients with chronic kidney disease reported comparable results. Lower baseline eGFR and higher baseline serum potassium concentrations are reported to be risk factors for hyperkalemia during esaxerenone therapy.

**Effect of Esaxerenone Therapy on Renal Function**

Albuminuria is associated with the development of end-stage kidney disease. A treatment-related reduction in albuminuria reduces the risk of end-stage kidney disease. Therefore, a change in albuminuria is considered as a surrogate marker of kidney function. Spironolactone and eplerenone decrease albuminuria, although both these agents increase the risk of hyperkalemia, thus leading to premature discontinuation. As observed in the present study, previous Phase IIb and Phase III studies have demonstrated that esaxerenone reduces albuminuria and is associated with few adverse events, namely hyperkalemia, independent of the degree of blood pressure reduction.

In this study we observed a relative improvement in eGFR during the 6-month period of esaxerenone therapy compared with the 6-month pre-treatment period. This study was designed based on the concept that eGFR declines gradually. Consistently, a Phase III study observed a statistically comparable trend in eGFR between the esaxerenone arm and the placebo arm.

Further studies are needed to analyze the mechanism of the potential renoprotective effects of esaxerenone. Given the initial drop in eGFR observed during a 12-week period of esaxerenone therapy in the Phase III study, an improvement in glomerular hyperfiltration may be a major mechanism. Understanding the comparative differences in renoprotective effects among different MRAs remains an area in need of further study. Determining which patients are most likely to benefit from specific MRAs requires further large prospective clinical trials. Given our findings, aggressive up-titration of esaxerenone, if tolerable, may be an option for resistant hypertension while also allowing for a unique renoprotective effect.

**Study Limitations**

In this small study we examined comprehensive clinical data obtained 6 months before and after the initiation of esaxerenone. This is a proof-of-concept study for the newly introduced MRA esaxerenone. Further larger-scale studies are needed to validate our findings. We lack monthly trends in clinical data, including eGFR and urinalysis. We performed intragroup comparisons (pre- vs. post-treatment) but lacked a control group. Although the medications remained unchanged during both periods, nevertheless there may have been uninvestigated confounders or covariates that may have had unmeasured clinical effects. In our study, most patients did not have diabetes or proteinuria and had relatively preserved renal function (>60 mL/min/1.73 m²). Our findings are not generalizable to those patient subsets.

**Conclusions**

Esaxerenone may have renoprotective benefits when administered for the treatment of resistant hypertension. Further studies are needed to understand the ideal patient subset that may experience clinical benefit from esaxerenone.

**Acknowledgments / Sources of Funding**

None.

**Disclosures**

T.I. receives grant support from JSPS KAKENHI (JP20K17143). K.K. is a member of *Circulation Reports* Editorial Board.

**IRB Information**

This study was approved by the University of Toyama Ethics Committee (No. RCOI2019584).

**Data Availability**

The deidentified participant data will not be shared.

**References**

1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/ABC/ACPM/AGS/Apha/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* 2018; 71: e13 – e115.

2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/EHS guidelines for the management of arterial hypertension. *Eur Heart J* 2018; 39: 3021–3104.

3. Kim HJ, Lee MH, Jo SH, Seo WW, Kim SE, Kim JH, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease: Propensity score matching analysis. *Circ J* 2019; 83: 83 – 90.

4. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endothocirculatory primary hypertension. *J Hypertens* 2013; 31: 3 – 15.

5. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. *Circ Heart Fail* 2014; 7: 573 – 579.

6. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in...
patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Circ Heart Fail* 2014; 7: 51–58.

7. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. *Lancet* 2013; 382: 339–352.

8. Arai K, Homma T, Morikawa Y, Ubuwata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. *Eur J Pharmacol* 2015; 761: 226–234.

9. Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with Type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial. *Clin J Am Soc Nephrol* 2020; 15: 1715–1727.

10. Ito S, Itoh H, Rakugi H, Okuda Y, Iijima S. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. *Hypertens Res* 2021; 44: 489–497.

11. Araki E, Tanaka A, Inagaki N, Ito H, Ueki K, Murohara T, et al; on behalf of the Directors of the JCS and JDS. Diagnosis, prevention, and treatment of cardiovascular diseases in people with Type 2 diabetes and prediabetes: A consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. *Circ J* 2020; 85: 82–125.

12. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: A meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol* 2019; 7: 128–139.

13. Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of Type 2 diabetes with microalbuminuria: A randomized, double-blind, placebo-controlled, Phase II trial. *Clin J Am Soc Nephrol* 2019; 14: 1161–1172.

14. Sato A. Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect? *Hypertens Res* 2019; 42: 1841–1847.